In light of the COVID-19 crisis, LYPHE Group has secured an emergency planning agreement with the Home Office and the Office of Medicinal Cannabis in the Netherlands to allow for the first time ever the export of sublingual medical cannabis oil tinctures for patients into the UK.
During such challenging times it is deemed absolutely right that policies change on certain life or death situations whilst protecting the liberty of the nation. The UK is rushing in new laws over the coming days which shall ease the burden on frontline staff and increase the NHS workforce, whilst containing, managing, supporting, and protecting the population from COVID-19. However, LYPHE Group are working to ensure medical cannabis patients do not get left behind.
It might feel that during such unrest, with fear and panic widespread and an undefined end point to the crisis, patients that rely on the medicinal benefits of medical cannabis are not as important. This could not be further from reality. Now, more than ever, it is critical that seriously unwell patients that suffer from epilepsy, anxiety, chronic pain, and other chronic diseases receive the medicines they need to avoid adding more pressure to the NHS.